




CHIMERIC THERAPEUTICS

20
25

CHIMERIC

PIONEERS IN CELL THERAPY

AGM 2025





DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements

contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials





CHM CDH17 PROGRESS AS AT NOV 24TH, 2025

FIVE ONGOING STABLE DISEASE


Dose Level	Status	Notes
1 50m	Completed	4 pts treated 1 pt remains on study 12months ongoing Stable Disease
2 150m	Recruitment Ongoing	5 patients treated 4 pts achieved ongoing Stable Disease 1 pt awaiting results
3 450m	Recruitment underway	1 pt awaiting dosing assignment
Manufacturing	FDA GMP compliant	10 out of 10 successful runs

FDA FASTRACK GRANTED



CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Four Completes Responses, 1 Partial Response



Complete Response means that all visible or measurable signs of cancer have disappeared after treatment

Partial Response means the cancer has reduced by at least 50% but not entirely disappeared in response to treatment



SUMMARY

CHM CDH17

CHM 2101

9 patients treated
10/10 manufacturing runs
Tumour shrinkage observed
Manageable safety profile
No off-target effects

10

CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial at MD ANDERSON
Dose Escalation completed
First Line Dosing Underway – 7 dosed up to 20 patients
No safety issues to date



CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.com

